OPTIVAR® is for ocular use only and not for injection or oral use.
Carcinogenesis, Mutagenesis, Impairment Of Fertility
Azelastine hydrochloride administered orally for 24 months was not carcinogenic in rats and mice at
doses up to 30 mg/kg/day and 25 mg/kg/day, respectively. Based on a 30 ìL drop size, these doses were
approximately 25,000 and 21,000 times higher than the maximum recommended ocular human use level
of 0.001 mg/kg/day for a 50 kg adult.
Azelastine hydrochloride showed no genotoxic effects in the Ames test, DNA repair test, mouse
lymphoma forward mutation assay, mouse micronucleus test, or chromosomal aberration test in rat bone
marrow. Reproduction and fertility studies in rats showed no effects on male or female fertility at oral
doses of up to 25,000 times the maximum recommended ocular human use level. At 68.6 mg/kg/day
(57,000 times the maximum recommended ocular human use level), the duration of the estrous cycle was
prolonged and copulatory activity and the number of pregnancies were decreased. The numbers of
corpora lutea and implantations were decreased; however, the implantation ratio was not affected.
Pregnancy Category C. Azelastine hydrochloride has been shown to be
embryotoxic, fetotoxic, and teratogenic (external and skeletal abnormalities) in mice at an oral dose of
68.6 mg/kg/day (57,000 times the recommended ocular human use level). At an oral dose of 30
mg/kg/day (25,000 times the recommended ocular human use level), delayed ossification (undeveloped
metacarpus) and the incidence of 14th rib were increased in rats. At 68.6 mg/kg/day (57,000 times the
maximum recommended ocular human use level) azelastine hydrochloride caused resorption and
fetotoxic effects in rats. The relevance to humans of these skeletal findings noted at only high drug
exposure levels is unknown.
There are no adequate and well-controlled studies in pregnant women. OPTIVAR® should be used
during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether azelastine hydrochloride is excreted in human milk. Because many drugs are
excreted in human milk, caution should be exercised when OPTIVAR® is administered to a nursing
Safety and effectiveness in pediatric patients below the age of 3 have not been established.
No overall differences in safety or effectiveness have been observed between elderly and younger